The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH CLL 2022 | Selecting CLL patients for CAR-T therapy
Marco Ruella, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, discusses the selection of chronic lymphocytic leukemia (CLL) patients for chimeric antigen receptor T-cell (CAR-T) therapy. Dr Ruella explains that patients who will likely benefit the most from CAR-T clinical trials are those that are younger and have high-risk disease, as they are less likely to respond to small molecule inhibition in the long-term. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
